Nifurtimox-efl ornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis : a multicentre , randomised , phase III , non-inferiority trial

@inproceedings{Priotto2009NifurtimoxeflOC,
  title={Nifurtimox-efl ornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis : a multicentre , randomised , phase III , non-inferiority trial},
  author={Gerardo Priotto and Serena Kasparian and Wilfried Mutombo and Daniel Ngouama and Sara Ghorashian and Ute Arnold and Salah Ghabri and Elisabeth Baudin and Vincent Buard and Serge Kazadi-Kyanza and M{\'e}dard Ilunga and Willy Mutangala and Gabriele Pohlig and Caecilia Schmid and Unni Karunakara and Els Torreele and Victor Betu Ku Mesu Kande},
  year={2009}
}
Background Human African trypanosomiasis (HAT; sleeping sickness) caused by Trypanosoma brucei gambiense is a fatal disease. Current treatment options for patients with second-stage disease are toxic, ineff ective, or impractical. We assessed the effi cacy and safety of nifurtimox-efl ornithine combination therapy (NECT) for second-stage disease compared with the standard efl ornithine regimen. 
17 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Sudan: cohort study

  • C Schmid, M Richer, CM Bilenge
  • BMJ
  • 2008

Nifurtimox - efl ornithine combination therapy for second - stage Trypanosoma brucei gambiense sleeping sickness : a randomized clinical trial in Congo

  • C Burri, S Nkunku, A Merolle, T Smith, J Blum, R Brun
  • Clin Infect Dis
  • 2007

ornithine for late-stage sleeping sickness in Uganda: a case series

  • G Priotto, S Kasparian, D Ngouama
  • PLoS Negl Trop Dis 2007;
  • 2007

Similar Papers

Loading similar papers…